

the group consisting of oligonucleotides, polymers as artificial antibodies, and phage display binding sites; and

b. detecting the presence of human iNOS protein in said sample, said specific binding entity recognizing human iNOS protein.

64 (Newly Added). The method of claim 62 in which said region of human iNOS protein is selected from the group consisting of the sequences: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDLQYHNLSKQQN (SEQ ID NO 26), NNNVEKAPCATSSPVTQD and SPVTQDDLQYHNLSKQQN (SEQ ID NO 29), PALVQGILERVVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQRLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

65 (Newly Added). The method of claim 64 in which said region of human iNOS protein is selected from the group consisting of the sequences: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDLQYHNLSKQQN (SEQ ID NO 26), NNNVEKAPCATSSPVTQD and SPVTQDDLQYHNLSKQQN (SEQ ID NO 29), PALVQGILERVVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQRLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

66 (Newly Added). The method of claim 62 in which said immunoassay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

67 (Newly Added). The method of claim 62 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

68 (Newly Added). The method of claim 62 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

69 (Newly Added). An immunoassay method for a sample comprising the steps of:

a. contacting the sample with a specific binding entity reactive to mimics of human iNOS protein without cross-reacting with human nNOS protein or human eNOS protein;

b. detecting the presence of human iNOS protein in said sample, said specific binding entity recognizing mimics of human iNOS protein.

70 (Newly Added). The method of claim 69 in which said specific binding entity is selected from the group consisting of: peptides, recombinant peptides, fusion proteins, fusion peptides, phage displayed proteins, phage displayed peptides, peptide libraries, and peptide analogue libraries.

71 (Newly Added). The method of claim 69 in which said region of human iNOS protein is selected from the group consisting of the sequences: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDIQLQYHNLSKQQN (SEQ ID NO 26), NNNVEKAPCATSSPVTQD and SPVTQDDIQLQYHNLSKQQN (SEQ ID NO 29), PALVQGILERVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQRLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

72 (Newly Added). The method of claim 69 in which said immunoassay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

73 (Newly Added). The method of claim 69 in which said immunoassay is a clinical diagnostic assay.

74 (Newly Added). The method of claim 69 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

75 (Newly Added). The method of claim 48 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

76 (Newly Added). The method of claim 69 in which said specific binding entity is any one of the peptide analogues of Table VII.

77 (Newly Added). The method of claim 69 in which said specific binding entity is any one of the peptide analogues of Table IX.

78 (Newly Added). The assay of claim 69 which is of the type selected from the group consisting of: IFA, linear or radial flow, Western Blot, ELISA, dip stick, fluorescent polarization, enzyme capture, and RIA.

79 (Newly Added). The assay of claim 62 which is of the type selected from the group consisting of: IFA, linear or radial flow, Western Blot, ELISA, dip stick, fluorescent polarization, enzyme capture, and RIA.

80 (Newly Added). The method of claim 76 in which said specific binding entity is a peptide analogue having the sequence: VTQDDLQ (SEQ ID NO 89).

81 (Newly Added). The method of claim 77 in which said specific binding entity is a peptide analogue having the sequence: VQGILERV (SEQ ID NO 120).